RT @synovialjoints: Exploring new mode of action for treatment of AS. In BE AGILE study, Bimekizumab (BKZ) provides furt
Tweet Content
Exploring new mode of action for treatment of AS. In BE AGILE study, Bimekizumab (BKZ) provides further sustained long-term improvements post 48 weeks in key efficacy outcome measures to 96 weeks of treatment @RheumNow #ACR20 Abstr#1364 https://t.co/972AvDNJDq
Show on Archive Page
On
Display in Search Results
On